Metabolism in HD: Still a relevant mechanism?
Authors:
- 13 August 2014
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 29 (11) , 1366-1374
Abstract
The polyglutamine expansion within huntingtin is the causative factor in the pathogenesis of Huntington's disease (HD). Although the underlying mechanisms by which mutant huntingtin causes neuronal dysfunction and degeneration have not been fully elucidated, compelling evidence suggests that mitochondrial dysfunction and compromised energy metabolism are key players in HD pathogenesis. Longitudinal studies of HD subjects have shown reductions in glucose utilization before the disease clinical onset. Preferential striatal neurodegeneration, a hallmark of HD pathogenesis, also has been associated with interrupted energy metabolism. Data from genetic HD models indicate that mutant huntingtin disrupts mitochondrial bioenergetics and prevents adenosine triphosphate (ATP) generation, implying altered energy metabolism as an important component of HD pathogenesis. Here we revisit the evidence of abnormal energy metabolism in the central nervous system of HD patients, review our current understanding of the molecular mechanisms underlying abnormal metabolism induced by mutant huntingtin, and discuss the promising therapeutic development by halting abnormal metabolism in HD. © 2014 International Parkinson and Movement Disorder SocietyKeywords
This publication has 110 references indexed in Scilit:
- The Sirtuin 2 Inhibitor AK-7 Is Neuroprotective in Huntington’s Disease Mouse ModelsCell Reports, 2012
- Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's diseaseMolecular and Cellular Neuroscience, 2012
- Early Alterations of Brain Cellular Energy Homeostasis in Huntington Disease ModelsJournal of Biological Chemistry, 2012
- Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathwayNature Medicine, 2011
- Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activityNature Medicine, 2011
- Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's diseaseNeurobiology of Disease, 2011
- Impaired mitochondrial trafficking in Huntington's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Mitochondrial calcium function and dysfunction in the central nervous systemBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2009
- Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathiesProceedings of the National Academy of Sciences, 2008
- Selective defect of in vivo glycolysis in early Huntington's disease striatumProceedings of the National Academy of Sciences of the United States of America, 2007